Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 654976
                    [Title] => Roche posts solid results in 2010
                    [Summary] => 
The Roche Group posted solid overall results in 2010. Group sales were stable in local currencies at 47.5 billion Swiss francs.
                    [DatePublished] => 2011-02-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 590859
                    [Title] => New hope for children with systemic juvenile idiopathic arthritis
                    [Summary] => 
Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
                    [DatePublished] => 2010-07-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ACTEMRA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 654976
                    [Title] => Roche posts solid results in 2010
                    [Summary] => 
The Roche Group posted solid overall results in 2010. Group sales were stable in local currencies at 47.5 billion Swiss francs.
                    [DatePublished] => 2011-02-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Business
                    [SectionUrl] => business
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 590859
                    [Title] => New hope for children with systemic juvenile idiopathic arthritis
                    [Summary] => 
Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic Arthritis (sJIA), a severe childhood arthritis, where there are no currently licensed treatments.
                    [DatePublished] => 2010-07-08 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche posts solid results in 2010

February 8, 2011 - 12:00am

The Roche Group posted solid overall results in 2010. Group sales were stable in local currencies at 47.5 billion Swiss francs.

Business

New hope for children with systemic juvenile idiopathic arthritis

July 8, 2010 - 12:00am

Roche announced that new data being presented at the European League Against Rheumatism (EULAR) congress demonstrates that Actemra is highly effective in improving the signs and symptoms of systemic Juvenile Idiopathic...

Science and Environment